Catalyst Wire Dossier Catalyst Wire Dossier

Sacituzumab govitecan-hziy

sacituzumab govitecan-hziy · Gilead Sciences
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Sacituzumab govitecan-hziy, covering 2021-04-06 to 2025-01-29. Get the full timeline:

Most recent: Clinical Trial Update: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer [Phase 2]

See pricing